SCHEMBL16208440

SCHEMBL16208440

Cc1ccc(NC(=O)CSc2nc3cccnc3[nH]2)cc1

nearest known ligand 0.71

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 2/20 0.71
▸ LMNA P02545 4/20 0.57
▸ MAPT P10636 6/20 0.56
▸ GAA P10253 1/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ THRB P10828 2/20 0.55
▸ HTT P42858 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ POLB P06746 2/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16208409 0.89 TSHR (0.59) MPOLMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL16208365 0.88 MAPT (0.56) MPOLMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL16208435 0.88 MPO (0.73) MPOLMNAMAPTALDH1A1HTT
SCHEMBL17624905 0.86 MAPT (0.74) MPOLMNAMAPTALDH1A1THRB
SCHEMBL17712438 0.84 MAPT (0.64) MPOLMNAMAPTGAAPOLB
SCHEMBL15347348 0.83 MPO (1.00) MPOLMNAMAPTGAAALDH1A1
SCHEMBL20305142 0.83 ENPP1 (0.74) LMNAALDH1A1HTTSMN1; SMN2TDP1
SCHEMBL6212573 0.81 MPO (0.73) MPOLMNAMAPTGAAALDH1A1
SCHEMBL17531756 0.76 MPO (0.73) MPOLMNAMAPTGAAALDH1A1
SCHEMBL12230246 0.74 KMT2A (0.86) MAPTGAAALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 — — US disclosed
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 — — US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 — — US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 — — US disclosed
WO-2014176258-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2014-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS CFTR, SLC11A2, MRPS18A MPO 981/4885LMNA 4827/4885MAPT 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback